STOK Stoke Therapeutics Inc
Price (delayed)
$6.6
Market cap
$356.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$228.86M
Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of
Highlights
The company's gross profit has surged by 118% QoQ
The revenue has soared by 118% from the previous quarter
Stoke Therapeutics's quick ratio has decreased by 17% YoY but it has increased by 13% from the previous quarter
Key stats
What are the main financial stats of STOK
Market
Valuations
Earnings
Shares outstanding
54.08M
Market cap
$356.91M
Enterprise value
$228.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
9.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
Revenue
$36.56M
Gross profit
$36.56M
Operating income
-$101.37M
Net income
-$88.98M
EBIT
-$101.62M
EBITDA
-$97.18M
Free cash flow
-$87.05M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.61
Book value per share
$4.32
Revenue per share
$0.68
TBVPS
$5.03
Total assets
$271.56M
Total liabilities
$42.53M
Debt
$0
Equity
$229.02M
Working capital
$192.7M
Debt to equity
0
Current ratio
5.81
Quick ratio
5.42
Net debt/EBITDA
1.32
Margins
Efficiency
Dividend
EBITDA margin
-265.8%
Gross margin
100%
Net margin
-243.4%
Operating margin
-277.3%
Return on assets
-33%
Return on equity
-42.2%
Return on invested capital
-158.2%
Return on capital employed
-43.9%
Return on sales
-278%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STOK stock price
How has the Stoke Therapeutics stock price performed over time
Intraday
5.94%
1 week
-10.81%
1 month
-15.92%
1 year
-49.54%
YTD
-40.16%
QTD
-0.75%
Financial performance
How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$36.56M
Gross profit
$36.56M
Operating income
-$101.37M
Net income
-$88.98M
Gross margin
100%
Net margin
-243.4%
The company's gross profit has surged by 118% QoQ
The revenue has soared by 118% from the previous quarter
STOK's net margin has surged by 80% year-on-year and by 61% since the previous quarter
The operating margin has soared by 79% YoY and by 60% from the previous quarter
Growth
What is Stoke Therapeutics's growth rate over time
Valuation
What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
1.53
P/S
9.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
The EPS has grown by 31% YoY and by 21% from the previous quarter
The P/B is 58% below the 5-year quarterly average of 3.4 and 55% below the last 4 quarters average of 3.2
Stoke Therapeutics's equity has increased by 44% YoY
The revenue has soared by 118% from the previous quarter
The price to sales (P/S) is 80% lower than the last 4 quarters average of 46.7
Efficiency
How efficient is Stoke Therapeutics business performance
The ROS has soared by 79% YoY and by 60% from the previous quarter
STOK's return on invested capital has surged by 54% year-on-year and by 46% since the previous quarter
The ROE has increased by 26% year-on-year and by 22% since the previous quarter
STOK's ROA is up by 21% YoY and by 19% from the previous quarter
Dividends
What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STOK.
Financial health
How did Stoke Therapeutics financials performed over time
The total liabilities has contracted by 38% YoY and by 31% from the previous quarter
STOK's total assets is up by 19% YoY but it is down by 7% from the previous quarter
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has increased by 44% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.